Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987150 | 0.87 | LMNA (0.40) | ACEAKR1C3AKR1C1PLGPLAT | |
| SCHEMBL21987769 | 0.85 | APLNR (0.36) | GABRR1BTKAPLNRGABRPGABRD | |
| SCHEMBL21841571 | 0.82 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL26477614 | 0.79 | CHRNB2 (0.39) | — | |
| SCHEMBL26477713 | 0.79 | CHRNB2 (0.39) | — | |
| SCHEMBL18498482 | 0.79 | CHRNB2 (0.39) | — | |
| SCHEMBL14294174 | 0.77 | — | — | |
| SCHEMBL18498495 | 0.76 | HRH3 (0.37) | BTK | |
| SCHEMBL18498470 | 0.74 | EPHX1 (0.33) | — | |
| SCHEMBL24906952 | 0.71 | ACE (0.58) | ACEAKR1C3AKR1C1GABRR1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20230037920-A1 | PAN-TACTIC CRYSTALLINE AND RECYCLABLE POLYTHIOESTERS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2023-02-09 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021113325-A1 | PAN-TACTIC CRYSTALLINE AND RECYCLABLE POLYTHIOESTERS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885 |
| US-20230037920-A1 | PAN-TACTIC CRYSTALLINE AND RECYCLABLE POLYTHIOESTERS | PARG, PLEKHA1, PANK1 | ACE 3577/4885AKR1C3 1297/4885AKR1C1 1817/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885 |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ACE 1256/4885AKR1C3 2382/4885AKR1C1 3203/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885 |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ACE 661/4885AKR1C3 1159/4885AKR1C1 1597/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.